Rolapitant API is a selective neurokinin-1 (NK1) receptor antagonist used as an antiemetic active pharmaceutical ingredient. The pharmaceutical substance is supplied in the hydrochloride form, with the approved drug substance identified as rolapitant hydrochloride monohydrate. Rolapitant is used in combination with other antiemetic agents for the prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy.
Rolapitant is a synthetic, stereochemically defined small-molecule API with three defined stereocenters. FDA substance-registration data identifies the hydrochloride monohydrate as the relevant salt/solvate form.
The pharmaceutical form of interest is Rolapitant Hydrochloride Monohydrate. FDA GSRS identifies its molecular composition as C25H26F6N2O2·HCl·H2O, with a molecular weight of 554.95 g/mol. The substance has the FDA UNII 57O5S1QSAQ.
The anhydrous hydrochloride form is separately identified by FDA as C25H26F6N2O2·HCl, with a molecular weight of 536.94 g/mol, demonstrating the importance of distinguishing the hydrate form from the anhydrous salt when specifying the API.
Rolapitant hydrochloride monohydrate is a synthetic organofluorine compound containing a diazaspiro framework, phenyl group and bis(trifluoromethyl)phenyl substituent. Its stereochemical configuration is an important part of the API identity.
PubChem identifies the monohydrate as the hydrochloride hydrate of rolapitant and gives the CAS Registry Number 914462-92-3. The parent rolapitant has the molecular formula C25H26F6N2O2 and molecular weight 500.5 g/mol.
The API is structurally designed to interact selectively with the NK1 receptor and inhibit signaling mediated by substance P, an endogenous neuropeptide involved in the emetic response.
Rolapitant hydrochloride API is primarily associated with pharmaceutical formulations for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV).
Its pharmaceutical application includes use:
FDA documentation describes rolapitant as an NK1 receptor antagonist and identifies its use for prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy.
Rolapitant is a selective neurokinin-1 (NK1) receptor antagonist.
The NK1 receptor is activated by substance P, a neuropeptide involved in the transmission of emetic signals. Rolapitant competitively blocks substance P from binding to the NK1 receptor, thereby reducing NK1-mediated signaling associated with nausea and vomiting.
Because of its prolonged pharmacological activity, rolapitant is particularly relevant to the prevention of delayed-phase chemotherapy-induced nausea and vomiting. FDA documentation identifies rolapitant as a substance P/NK1 receptor antagonist.
Quality control of Rolapitant API requires comprehensive characterization of the chemically defined drug substance, including confirmation of identity, stereochemical integrity, assay, related substances and control of process-related impurities.
FDA's review of rolapitant hydrochloride drug substance included evaluation of the manufacturer's proposed specifications and impurity-control strategy. The FDA review states that the drug-substance impurity specifications met the applicable ICH Q3A qualification threshold for drug substances with a maximum daily dose of 2 g or less. Potential genotoxic impurities were also assessed using an ICH M7-based strategy.
Typical analytical controls for a pharmaceutical-grade API may include:
Exact numerical release criteria should be based on the applicable validated API specification rather than assumed universal limits.
Rolapitant hydrochloride API is manufactured through controlled synthetic processes followed by purification, isolation and conversion to the specified pharmaceutical salt/hydrate form.
Because rolapitant contains multiple stereocenters, manufacturing controls should maintain the required stereochemical identity and minimize formation of undesired stereoisomeric impurities.
A pharmaceutical-grade manufacturing process should incorporate controlled reaction conditions, impurity monitoring, validated purification procedures, solvent controls, appropriate crystallization or isolation steps and final quality testing.
FDA's CMC review demonstrates that the rolapitant hydrochloride drug substance was subject to a defined specification and impurity-control strategy during regulatory review.
Rolapitant hydrochloride monohydrate is a defined hydrochloride hydrate of the active moiety.
Key chemical characteristics include:
These values are supported by FDA's Global Substance Registration System.
PubChem reports an XLogP3-AA value of approximately 4.4 for the parent rolapitant, reflecting its relatively lipophilic molecular character.
Rolapitant API should be packaged in suitable pharmaceutical-grade containers that protect the material from contamination, moisture and environmental exposure.
The packaging configuration should be compatible with the validated stability characteristics of the hydrochloride monohydrate and the requirements of the applicable API specification.
Recommended storage conditions should be established from validated stability data and the manufacturer's approved specification. Containers should remain appropriately closed during storage and handling.
A qualified Rolapitant API manufacturer can provide appropriate technical and quality documentation according to customer and regulatory requirements, including:
Documentation availability depends on the manufacturing site, API specification and intended regulatory market.
Choosing a qualified Rolapitant API manufacturer in India can support pharmaceutical companies involved in antiemetic and oncology supportive-care product development.
A reliable manufacturing partner should maintain:
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |